The company said it will look to obtain regulatory approval in additional countries to accelerate the analyzer's market introduction in Asia and Africa.
Through its Access to COVID-19 Tools-Accelerator program, or ACT-A, WHO hopes to quickly identify and scale up high performing rapid antigen-based diagnostics.
Validation for the BioSure COVID-19 Antibody Self-Test, which provides results in 10 minutes and requires no training, is currently underway, the firms said.
